EP4021905 - INHIBITORS OF ADRENORECEPTOR ADRAC2 [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 17.02.2023 Database last updated on 26.06.2024 | |
Former | Request for examination was made Status updated on 03.06.2022 | ||
Former | The international publication has been made Status updated on 14.05.2021 | ||
Former | unknown Status updated on 10.11.2020 | Most recent event Tooltip | 28.10.2023 | New entry: Renewal fee paid | Applicant(s) | For all designated states Bayer Aktiengesellschaft Kaiser-Wilhelm-Allee 1 51373 Leverkusen / DE | [2022/27] | Inventor(s) | 01 /
DELBECK, Martina Müllerweg 10 42579 Heiligenhaus / DE | 02 /
HAHN, Michael Rietherbach 42D 40764 Langenfeld / DE | 03 /
MÜLLER, Thomas Parkstraße 24 40764 Langenfeld / DE | 04 /
DIETZ, Lisa An der Grenze 17 42111 Wuppertal / DE | 05 /
PLATZK, Magdalena 200 Hyslop Rd Brookline, MA 02445 / US | 06 /
MEIBOM, Daniel In den Birken 62b 42113 Wuppertal / DE | 07 /
BUCHGRABER, Philipp Kastanienallee 25 10435 Berlin / DE | 08 /
LINDNER, Niels Düsseldorfer Strasse 47 42115 Wuppertal / DE | 09 /
BECKER-PELSTER, Eva Maria Düsseler Höhe 22 42327 Wuppertal / DE | 10 /
SCHMECK, Carsten Carl-Friedrich-Goerdeler-Straße 24 45472 Mülheim / DE | [2022/27] | Representative(s) | BIP Patents c/o Bayer Intellectual Property GmbH Alfred-Nobel-Straße 50 40789 Monheim am Rhein / DE | [2022/27] | Application number, filing date | 20800159.4 | 05.11.2020 | [2022/27] | WO2020EP81097 | Priority number, date | EP20190207536 | 06.11.2019 Original published format: EP 19207536 | [2022/27] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021089683 | Date: | 14.05.2021 | Language: | EN | [2021/19] | Type: | A1 Application with search report | No.: | EP4021905 | Date: | 06.07.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 14.05.2021 takes the place of the publication of the European patent application. | [2022/27] | Search report(s) | International search report - published on: | EP | 14.05.2021 | Classification | IPC: | C07D413/14, C07D417/14, A61K31/454, A61P9/00, A61P11/00, A61P25/00 | [2022/27] | CPC: |
C07D417/14 (EP,IL,KR);
C07D417/12 (US);
A61K31/4545 (EP,KR);
A61K31/4725 (EP);
A61K31/55 (EP);
A61K45/06 (EP);
A61P11/00 (EP,IL,KR);
A61P25/00 (EP,IL,KR);
A61P9/00 (EP,IL,KR);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/27] | Extension states | BA | 30.03.2022 | ME | 30.03.2022 | Validation states | MA | 30.03.2022 | TN | 30.03.2022 | Title | German: | INHIBITOREN VON ADRENOREZEPTOR ADRAC2 | [2022/27] | English: | INHIBITORS OF ADRENORECEPTOR ADRAC2 | [2022/27] | French: | INHIBITEURS DE L'ADRÉNORÉCEPTEUR ADRAC2 | [2022/27] | Entry into regional phase | 30.03.2022 | National basic fee paid | 30.03.2022 | Designation fee(s) paid | 30.03.2022 | Examination fee paid | Examination procedure | 30.03.2022 | Examination requested [2022/27] | 30.03.2022 | Date on which the examining division has become responsible | 28.10.2022 | Amendment by applicant (claims and/or description) | 21.02.2023 | Despatch of a communication from the examining division (Time limit: M06) | 21.08.2023 | Reply to a communication from the examining division | Fees paid | Renewal fee | 26.10.2022 | Renewal fee patent year 03 | 27.10.2023 | Renewal fee patent year 04 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]WO2008060568 (NEUROGEN CORP [US], et al) [A] 1-16* claims 1, 85, 86; compounds 76-80 *; | [A]WO2015091415 (BAYER PHARMA AG [DE]) [A] 1-16 * page 161; examples 43, 45, 50, 53, 54, 56, 70-98, 104, 105; claim 1 *; | [AD]WO2015091420 (BAYER PHARMA AG [DE]) [AD] 1-16 * page 74; claim 1 * | by applicant | US3966781 | WO0006568 | WO0006569 | WO0119355 | WO0119776 | WO0119778 | WO0119780 | WO0242301 | WO02070462 | WO02070510 | WO03095451 | WO2008052934 | WO2011147809 | WO2012004258 | WO2012028647 | WO2012059549 | WO2012112363 | WO2015017305 | WO2015091420 | WO2017097792 | WO2017097671 | WO2018015196 | WO2018228907 | WO2018228909 | - GYIRES et al., "a Adrenoceptor subtypes-mediated physiological, pharmacological actions", Neurochemistry International, (20090000), vol. 55, doi:10.1016/j.neuint.2009.05.014, pages 447 - 453, XP026562407 DOI: http://dx.doi.org/10.1016/j.neuint.2009.05.014 | - TANLIMBIRD, "The a Adrenergic Receptors", Adrenergic Receptors in the 21st Century/Receptors, (20050000), pages 241 - 265 | - JORDAN ASWHITE DPLO YL et al., "Airway dilator muscle activity and lung volume during stable breathing in obstructive sleep apnea", Sleep, (20090000), vol. 32, no. 3, pages 361 - 8 | - HOMER R.L., "Neuromodulation of hypoglossal motoneurons during sleep", Respir Physiol Neurobiol, (20080000), vol. 164, no. 1-2, doi:10.1016/j.resp.2008.06.012, pages 179 - 196, XP025561340 DOI: http://dx.doi.org/10.1016/j.resp.2008.06.012 | - VRINTS et al., Acta Clin Belg, (20130000), vol. 68, pages 169 - 78 | - HEIN L et al., "Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission", Nature, (19990000), vol. 402, no. 6758, pages 181 - 184 | - HOLLANDT et al., HNO, (20000000), vol. 48, pages 628 - 634 | - ECKERT D.J. et al., "Central sleep apnea: Pathophysiology and treatment", Chest, (20070000), vol. 131, no. 2, pages 595 - 607 | - ARENS C., "Position paper of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery and the German Society of Phoniatrics and Pediatric Audiology - current state of clinical and endoscopic diagnostics, evaluation, and therapy of swallowing disorders in children and adults", Laryngorhinootologie, (20150300), vol. 1, pages 306 - 54 | - KARKOS PD, "Current evaluation of the dysphagic patient", Hippokratia, (20090700), vol. 13, no. 3, pages 141 - 6 | - YAMANISHI T., "Alpha2-adrenoceptors coordinate swallowing and respiration", J Dent Res, (20100000), vol. 89, no. 3, pages 258 - 2639 | - KANAGY, Clinical Science, (20050000), vol. 109, pages 431 - 437 | - GYIRES et al., "a -Adrenoceptor subtypes-mediated physiological, pharmacological actions", Neurochemistry International, (20090000), vol. 55, doi:10.1016/j.neuint.2009.05.014, pages 447 - 453, XP026562407 DOI: http://dx.doi.org/10.1016/j.neuint.2009.05.014 | - CHOTANI et al., "Silent a adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries", Am J Physiol, (20000000), vol. 278, pages H1075 - H1083 | - CHOTANI et al., "Distinct cAMP signaling pathways differentially regulate a adrenenoxceptor expression: role in serum induction in human arteriolar smooth muscle cells", Am J Physiol Heart Circ Physiol, (20050000), vol. 288, pages H69 - H76 | - KEENANPORTER, "a Adrenergic receptors in platelets from patients with Raynaud's syndrome", Surgery, (19830000), vol. V94, no. 2 | - "Isotopic Compositions of the Elements 1997", Pure Appl. Chem., (19980000), vol. 70, no. 1, pages 217 - 235 | - H. J. LEIS et al., Curr. Org. Chem., (19980000), vol. 2, page 131 | - ESAKI et al., Tetrahedron, (20060000), vol. 62, page 10954 | - ESAKI et al., Chem. Eur. J., (20070000), vol. 13, page 4052 | - J. R. MORANDI et al., J. Org. Chem., (19690000), vol. 34, no. 6, page 1889 | - N. H. KHAN, J. Am. Chem. Soc., (19520000), vol. 74, no. 12, page 3018 | - S. CHANDRASEKHAR et al., Tetrahedron, (20110000), vol. 52, no. 3865 | - HANZLIK et al., J. Org. Chem., (19900000), vol. 55, pages 3992 - 3997 | - R. P. HANZLIK et al., Biochem. Biophys. Res. Commun., (19890000), vol. 160, page 844 | - P. J. REIDER et al., J Org. Chem., (19870000), vol. 52, pages 3326 - 3334 | - M. JARMAN et al., Carcinogenesis, (19930000), vol. 16, no. 4, pages 683 - 688 | - J. ATZRODT et al., Angew. Chem., Int. Ed., (20070000), vol. 46, page 7744 | - K. MATOISHI et al., J. Chem. Soc, Chem. Commun., (20000000), pages 1519 - 1520 | - A. STREITWIESER et al., J. Am. Chem. Soc., (19630000), vol. 85, page 2759 | - C. L. PERRIN et al., J. Am. Chem. Soc., (20070000), vol. 129, page 4490 | - C. L. PERRIN et al., J. Am. Chem. Soc., (20030000), vol. 125, page 15008 | - C. L. PERRIN, Advances in Physical Organic Chemistry, vol. 44, page 144 | - C. L. PERRIN et al., J. Am. Chem. Soc., (20050000), vol. 127, page 9641 | - B. TESTA et al., Int. J. Pharm., (19840000), vol. 19, no. 3, page 271 | - D. J. KUSHNER et al., Can. J. Physiol. Pharmacol., (19990000), vol. 77, page 79 | - A. E. MUTLIB et al., Toxicol. Appl. Pharmacol., (20000000), vol. 169, page 102 | - A. M. SHARMA et al., Chem. Res. Toxicol., (20130000), vol. 26, page 410 | - UETRECHT et al., Chemical Research in Toxicology, (20080000), vol. 21, no. 9, page 1862 | - A. J. MORALES et al., The 15th North American Meeting of the International Society of Xenobiotics, (20081012), vol. 285 | - C. J. WENTHUR et al., J. Med. Chem., (20130000), vol. 56, page 5208 | - F. SCHNEIDER et al., Arzneim. Forsch. Drug. Res., (20060000), vol. 56, page 295 | - F. MALTAIS et al., J. Med. Chem., (20090000), vol. 52, page 7993 | - Citation of NMR Peaklist Data within Patent Applications, (20140801), URL: http://www.researchdisclosure.com/searching-disclosures | - CAS, no. 1799475-27-6 | - CHENG YPRUSOFF WH, "Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction", Biochem Pharmacol, vol. 22, no. 23, doi:10.1016/0006-2952(73)90196-2, pages 3099 - 108, XP000942582 DOI: http://dx.doi.org/10.1016/0006-2952(73)90196-2 | - WUNDER F.KALTHOF B.MULLER T.HUESER J., "Functional Cell-Based Assays in Microliter Volumes for Ultra-High Throughput Screening", Combinatorial Chemistry & High Throughput Screening, (20080000), vol. 11, no. 7, pages 495 - 504 | - WIRTH et al., Sleep, (20130000), vol. 36, pages 699 - 708 |